Semaglutide effects on cardiovascular outcomes in individuals with overweight or obesity who do not have diabetes: a systematic review DOI Creative Commons

Anna Klasa,

Aleksandra Sobaś,

Kamil Biedka

et al.

MEDICAL SCIENCE PULSE, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 31, 2024

Background: Obesity causes organ dysfunction through several pathophysiological mechanisms, such as the physical impact of increased fat mass, presence ectopic in tissues and organs, metabolic effects, inflammatory mechanisms [1]. Prospective studies have shown that deposits are associated with cardiovascular outcomes independently other traditional risk factors. It has been proposed prothrombotic proinflammatory environment a significant role pathogenesis disease (CVD) [2]. The weight loss induced by anti-obesity drugs may improve risk, glucagon-like peptide-1 analogs - promote these benefits [3]. Glucagon-like receptor agonists (GLP-1Ras), semaglutide, direct effects at multiple sites, including glucose-dependent stimulation insulin secretion, suppression glucagon appetite reduction, delayed gastric emptying Aim study: This paper aims to summarize analyze current knowledge regarding semaglutide on individuals who overweight or obese but do not diabetes. Material methods: literature review was performed according PICO guidelines. MEDLINE database searched. following search query used: “semaglutide disease”. “Free full text” filter applied. Results: Analysis SELECT trial showed patients atherosclerotic CVD were obese, treatment 2–4 mg reduced major adverse events composite heart failure endpoints compared placebo [4]. In analysis STEP-HFpEF trial, better than improving failure-related symptoms reducing body participants obesity preserved ejection fraction [5]. According STEP 1 4 studies, reduce use antihypertensive lipid-lowering [6]. Conclusions: Semaglutide improves limitations reduces inflammation [7]. Despite promising results, further research is necessary assess long-term semaglutide.

Language: Английский

Preoperative Telerehabilitation Improves Outcomes After Cardiac Surgery DOI

Subodh Verma,

Makoto Mori,

Mario Gaudino

et al.

Journal of the American College of Cardiology, Journal Year: 2025, Volume and Issue: 85(8), P. 801 - 803

Published: Jan. 8, 2025

Language: Английский

Citations

1
Acute heart failure – transitioning from symptom-based care to remission DOI Creative Commons
Gad Cotter, Beth A. Davison, Douglas L. Mann

et al.

Journal of Cardiac Failure, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

During the last century characteristics of patients with heart failure (HF) and acute HF (AHF) have shifted from severe pump due to rheumatic, hypertensive ischemic disease older more obese multiple comorbidities. The pathophysiology AHF has in parallel that advanced, end-stage, caused by left ventricular dysfunction age, obesity comorbidity-related cardiovascular combined neurohormonal inflammatory dysregulation or "inflammaging". With advent blockers leading improved outcomes chronic HF, focus therapy also changed care directed at early symptom improvement therapies towards longer-term improvements quality life outcomes. Studies conducted 5 years suggest beneficial effects seen 4 pillars guideline-directed medical for mostly comprising blockade, can be extended when these are initiated rapidly uptitrated during admission after discharge. A recent pilot study (CORTAHF) suggested benefits treating markers activation anti-inflammatory therapies. Future studies should further examine whether blockade lead reversal disrupted underlying remission AHF.

Language: Английский

Citations

1
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives DOI Creative Commons

Kosuke Sawami,

Atsushi Tanaka, Koichi Node

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: Nov. 15, 2024

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology. GLP-1RA therapy has shown potential benefits reducing risk major adverse cardiovascular events improving kidney outcomes patients with at high for disease. More recent evidence expanding their to heart failure preserved ejection fraction clinically important renal without diabetes. Some sub-analyses large clinical trials suggest sodium-glucose cotransporter inhibitor combination may provide more significant reductions hospitalization composite than each alone. Moreover, addition finerenone this could potentially stronger cardiorenal protective benefits. Further studies are needed assess determine suitable patient population therapy. Graphical abstract Suspected impacts GLP-1RAs, SGLT2is, oncardiovascular outcomes. CV, cardiovascular; GLP-1RA, glucagon-like agonist; HFpEF, fraction; HFrEF, reduced MI, myocardial infarction; SGLT2i, inhibitor.

Language: Английский

Citations

8
The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model DOI Open Access

Sunhuo Li,

Coenraad Withaar, Patrícia Gonçalves‐Rodrigues

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 181, P. 117711 - 117711

Published: Nov. 30, 2024

Language: Английский

Citations

4
Lack of ALCAT1 enhances the protective effects of aerobic exercise on kidney in HFpEF mice DOI
Libin Zhang, Lili Feng, Yifang Zhao

et al.

Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123500 - 123500

Published: Feb. 1, 2025

Language: Английский

Citations

0
Myeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial DOI
Veraprapas Kittipibul, Andrew P. Ambrosy, Stephen J. Greene

et al.

Heart Failure Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Language: Английский

Citations

0
Elevated C-reactive protein and cardiovascular risk DOI
Jia Ee Chia, Song Peng Ang

Current Opinion in Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Purpose of review This critically examines the evolving role C-reactive protein (CRP) in cardiovascular disease (CVD), addressing its pathogenesis and relationship with various CVDs including coronary artery (CAD), heart failure, atrial fibrillation. Recent findings CRP is mechanistically implicated endothelial dysfunction, oxidative stress, plaque destabilization. studies demonstrate that lipid-lowering agents (statins, bempedoic acid) anti-inflammatory therapies (canakinumab, colchicine) reduce levels improve outcomes CAD. In elevated predicts adverse events, though evidence on phenotypes varies, novel (glucagon-like peptide-1 agonists, sodium-glucose cotransporter-2 inhibitors) lower independently weight loss. For fibrillation, correlates postoperative incidence recurrence postablation, data remain inconsistent. Guidelines offer differing opinion American College Cardiology Heart Association (ACC/AHA) guidelines cautiously endorsing for risk stratification intermediate-risk individuals, while European advise against routine use primary prevention, reflecting unresolved questions about CRP's additive value. Summary remains a pivotal inflammation biomarker CVD, yet causal clinical applicability require clarification. While CRP-guided show promise, discrepancies highlight need robust trials to determine whether targeting directly improves outcomes. Future research should focus pathophysiological mechanisms validate utility personalized CVD management.

Language: Английский

Citations

0
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment DOI Creative Commons

Richard Salvador,

Carla Moutinho, Carla Silva

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 399 - 399

Published: March 12, 2025

This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist, in treatment obesity and its related comorbidities. Originally developed for type 2 diabetes (DM2), SMG has shown significant efficacy weight reduction, with superior results compared to other treatments same class. Its effects include appetite suppression, increased satiety, improvements cardiovascular, renal, metabolic parameters. Studies such as SUSTAIN, PIONEER, STEP highlight superiority agonists anti-obesity drugs. The oral formulation showed promising initial results, higher doses (50 mg) showing losses comparable those subcutaneous administration. Despite benefits, there are challenges, regain after cessation treatment, gastrointestinal adverse effects, variability response. Future studies should explore strategies mitigate these identify predictive factors efficacy, expand therapeutic indications conditions insulin resistance. constant innovation this class drugs reinforces potential transform protocols chronic weight-related diseases.

Language: Английский

Citations

0
Cardiac Involvement and Heart Failure Staging in Patients with Systemic Sclerosis Without Pulmonary Arterial Hypertension DOI Open Access
Maria Isilda Oliveira, Bruno Bragança, José Rodrigues Gomes

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(7), P. 2211 - 2211

Published: March 24, 2025

Background/Objectives: Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by fibrosis and vascular damage, significantly increasing the risk of heart failure (HF). Methods: This cross-sectional study included 61 SSc patients (92% female, mean age 63 ± 13 years), excluding those with pulmonary arterial hypertension, referred to a tertiary hypertension center. HF stages were classified according updated guidelines. Clinical, echocardiographic, hemodynamic, functional capacity data analyzed in relation stages. Results: A total 48% had pre-symptomatic (5% stage A, 43% B), while 38% symptomatic (stage C). Advanced associated older (p = 0.02) multiorgan involvement 0.045) but not subtype or autoantibodies. Structural echocardiographic abnormalities prevalent (77% 10%, respectively). Markers elevated ventricular filling pressure such as left atrial volume 0.011) E/e' ratio 0.03) correlated severity. Functional impairment was observed lower 6 min walk test (6MWT) distance 0.017), reduced VO2 peak 0.015), increased VE/VCO2 slope 0.002). Resting artery wedge did correlate 0.93). 6MWT independently Conclusions: Preclinical are highly patients. staging linked severity, age, cardiovascular factors. tests (6MWT CPET) serve valuable tools for stratification. These findings highlight critical need comprehensive assessment targeted management strategies mitigate progression

Language: Английский

Citations

0
Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art DOI
Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou

et al.

Heart Failure Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Language: Английский

Citations

0